Related Experiment Video
Updated: May 18, 2026
06:17
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Plant-derived virus-like particles as vaccines
1Center for Infectious Diseases and Vaccinology, Biodesign Institute at Arizona State University, Tempe, AZ USA. Qiang.Chen.4@asu.edu
Human Vaccines & Immunotherapeutics
|September 22, 2012
Summary
Plants offer a fast, cost-effective method for producing virus-like particles (VLPs) vaccines. This review highlights plant expression systems for VLP vaccine development, showcasing their potential for rapid, economical vaccine production.
Area of Science:
- Biotechnology
- Vaccinology
- Molecular Biology
Background:
- Virus-like particles (VLPs) are safe, immunogenic vaccine platforms mimicking viral structures without genetic material.
- VLPs are effective carriers for foreign epitopes, leading to successful licensed vaccines.
- Current VLP production faces challenges in speed and cost.
Purpose of the Study:
- To review the role of plants as a novel, rapid, and economical production platform for VLP-based vaccines.
- To discuss the advantages of plant expression systems for VLP production.
- To present recent advancements and future prospects of plant-derived VLP vaccines.
Main Methods:
- Review of scientific literature on plant-based VLP production.
- Analysis of VLP expression, assembly, and immunogenicity in plant systems.
- Examination of clinical trial data and regulatory approvals for plant-derived biologics.
Main Results:
- Plant expression systems offer advantages in post-translational modifications, cost-effectiveness, speed, and scalability for VLP production.
- Successful expression and assembly of VLPs and chimeric derivatives in plants have been demonstrated.
- Clinical trials confirm the safety and efficacy of plant-derived VLPs, with recent FDA approval for plant-made biologics.
Conclusions:
- Plants represent a promising platform for the efficient and economical production of VLP-based vaccines.
- Advancements in "humanized" glycosylation plant lines enhance VLP vaccine potential.
- The synergy of plant expression systems and VLP technology is poised to drive future vaccine development and novel VLP applications.
Keywords:
Plant-derived vaccinecGMPchimeric VLPclinical trialdownstream processingglycosylationoral deliveryplant-derived VLPpurificationvaccinevaccine platformsvirus-like particle (VLP)More Related Videos
Related Concept Videos
01:29Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
00:56Viral Structure
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:28Introduction to Virus
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...